Cerebral amyloid angiopathy fluid biomarkers evaluation - Alzheimer*s Disease (CAFÉ-AD)

Cerebral amyloid angiopathy fluid biomarkers evaluation - Alzheimer*s Disease (CAFÉ-AD) - CAFE-AD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON48320

Enrollment

Registered

2020-01-23

Start date

2020-10-13

Completion date

Unknown

Last updated

2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ziekte van Alzheimer Cerebral amyloid angiopathy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Diagnosis of Alzheimer*s disease made according to recent clinical criteria (26) - Subjects are mentally competent to take a decision on participation. - Written informed consent - Age >55 years - CDR 0.5 or 1.0

Exclusion criteria

Exclusion criteria: Evidence of recent (

Design outcomes

Primary

Measure	Time frame
Biomarkers will first be evaluated for their suitability to serve as biomarkers by univariate testing (t-test in case of comparison of two groups) or ANOVA (comparison of more than two groups). Main comparisons will be between AD patients with radiological evidence of CAA and Controls (recruited via the CAFÉ project, file number 2017-3605) and between AD patients with radiological evidence of CAA versus AD patients without radiological evidence of CAA.	—

Measure

Time frame

Biomarkers will first be evaluated for their suitability to serve as biomarkers by univariate testing (t-test in case of comparison of two groups) or ANOVA (comparison of more than two groups). Main comparisons will be between AD patients with radiological evidence of CAA and Controls (recruited via the CAFÉ project, file number 2017-3605) and between AD patients with radiological evidence of CAA versus AD patients without radiological evidence of CAA.

—

Secondary

Measure	Time frame
Establishing correlations between the new neurochemical biomarkers on the one hand and neuroimaging and neuropsychological biomarkers on the other.	—

Countries

Netherlands

Outcome results